- Patients on pasireotide (SOM230) LAR were 63% more likely to achieve full biochemical control than those on Sandostatin LAR, the current standard of care[1] - Acromegaly, a rare endocrine disorder ...
Viatris Inc. (NASDAQ:VTRS) is one of the top cheap stocks under $20 to buy now. On December 18, Viatris Inc. (NASDAQ:VTRS) ...
PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...
Teva is introducing the only generic version of Novartis AG's Sandostatin LAR Depot, in the United States. Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe ...
Everolimus plus octreotide LAR extended time without tumor growth from 11.3 to 16.4 months versus octreotide LAR alone in advanced NET (carcinoid) patients[1] The study did not reach its primary ...
Viatris Inc. VTRS recently announced four regulatory achievements across multiple stages of its pipeline. These achievements outline the company’s R&D progress in 2025. VTRS will continuously work ...
Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide ...
The decision to discontinue Sandostatin 200mcg and 1000mcg is not due to manufacturing, product quality, safety, or efficacy concerns, according to the Company. The Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback